BIONOMICS LIMITED - Positive outcome of End-of-Phase 2 meeting with
U.S. Food and Drug Administration (FDA) inSeptember 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety Disorder - Company confirms agreement with the FDA on Phase 3 clinical program and alignment on nonclinical toxicology studies required for registration
- Company is on track for first patient dosed in the Phase 3 program planed for Q1’24
“We are grateful for FDA’s support and guidance and very pleased to reach an agreement on key elements of Phase 3 design and other nonclinical components required for registration”, said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “The FDA meeting outcomes provide external and independent validation of our position on the strength and Phase 3-enabling nature of the PREVAIL dataset. BNC210’s unique clinical profile seen in multiple anxiety disorders including SAD, Generalized Anxiety Disorder and in a panic model, was recently significantly enhanced by the positive results in Post-Traumatic Stress Disorder. BNC210, which has Fast-Track designation from the FDA for the acute treatment of SAD, has the potential to address a significant unmet need for the 17 million Americans suffering from SAD who currently don’t have fast acting and safe treatment options.”
On
1) the plan to conduct two randomized, placebo-controlled studies with single administration of BNC210 during a public speaking task;
2) the use of the Subjective Units of Distress Scale (SUDS) measured during a public speaking challenge as the primary efficacy endpoint;
3) the doses of BNC210 to be studied in Phase 3;
4) the sample size assumptions for the Phase 3 controlled studies based on PREVAIL findings;
5) the design elements of the open label safety study required to support the new drug application (NDA);
6) the size of the safety database to support the NDA; and
7) the nonclinical toxicology studies needed to support the NDA.
The Company anticipates beginning the Phase 3 program in Q1’24.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Company Secretary CoSec@bionomics.com.au | Investor Relations kgardner@lifesciadvisors.com | Investor Relations ccalabrese@lifesciadvisors.com |
About
Bionomics (NASDAQ:BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co., Inc.,
Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s plans to advance the development of its product candidates, the timing of achieving any development or regulatory milestones, and the comparability and potential of such product candidates, including to achieve any benefit or profile or any product approval or be effective. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the
2023 GlobeNewswire, Inc., source
